Comparative Pharmacology
Head-to-head clinical analysis: BARHEMSYS versus TORECAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BARHEMSYS versus TORECAN.
BARHEMSYS vs TORECAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BARHEMSYS (amisulpride) is a selective dopamine D2/D3 receptor antagonist. It also has weak affinity for serotonin 5-HT2A and 5-HT2B receptors, with no significant activity at other dopamine or serotonin receptor subtypes. Its antiemetic effect is primarily mediated through blockade of D2 receptors in the chemoreceptor trigger zone (CTZ).
TORECAN (thiethylperazine) is a phenothiazine derivative that acts primarily as a dopamine D2 receptor antagonist in the chemoreceptor trigger zone (CTZ) to exert antiemetic effects. It also possesses anticholinergic and antihistaminergic properties.
BARHEMSYS (amisulpride) 10 mg intravenously over 2 minutes, once daily for prevention of postoperative nausea and vomiting.
10 mg orally or intramuscularly every 6 to 8 hours as needed for nausea and vomiting.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours, supporting once-daily dosing in most patients.
Terminal elimination half-life: 6-8 hours. Clinical context: Allows twice-daily dosing; prolonged in renal impairment.
Renal excretion accounts for approximately 50% of the dose as unchanged drug; fecal elimination (including biliary) accounts for approximately 30-40%.
Primarily renal (60-70% as unchanged drug and metabolites); biliary/fecal (20-30%).
Category C
Category C
Antiemetic
Antiemetic